Q2 2027 McKesson Corporation Earnings Conference Call - MCKESSON CORP

Explicit Guidance:

• Fiscal 2027 Adjusted EPS: Raised to $45.60–$46.40 (previous range: $44.20–$45.00); implies 17–19% growth excluding prior year divestiture gains.
• Fiscal 2027 Revenue: Anticipated growth of 6–10%.
• Fiscal 2027 Operating Profit: Anticipated growth of 12–16%.
• Fiscal 2027 Effective Tax Rate: Expected to range between 18–19%; third quarter expected to have a higher rate than the fourth due to discrete tax timing.
• Fiscal 2027 Interest Expense: Expected on the high end of $380–$420 million.
• Fiscal 2027 Income from Non-Controlling Interests: Anticipated $290–$320 million.
• Fiscal 2027 Diluted Weighted Average Shares: Estimated 115.5–117.5 million.
• Fiscal 2027 Free Cash Flow: Anticipated $4.5–$4.9 billion.
• Fiscal 2027 Share Repurchases: Expect to repurchase approximately $5 billion of shares.
• Segment Outlook – North American Pharmaceutical: Revenue growth of 5–9%; Operating profit growth of 14–18%.
• Segment Outlook – Oncology & Multi-Specialty: Revenue growth of 20–24%; Operating profit growth of 18–22% (22–26% excluding prior year net gains).
• Segment Outlook – Prescription Technology Solutions: Revenue growth of 2.5–6.5%; Operating profit growth of 11–15%.
• Segment Outlook – Medical-Surgical Solutions: Revenue growth of 1–6%; Operating profit expected flat to down 4%.
• Corporate Expenses: Anticipated at the high end of $580–$640 million.
• Precision Medicine Group (PMG) Contribution: Estimated to add $0.10–$0.20 to Fiscal 2027 adjusted EPS, with heavier weighting in Q4; by end of Year 3, accretion estimated at $1.60–$1.80.

Business-Segment Outlook:

• North American Pharmaceutical: Growth driven by stable prescription volumes, increasing demand for specialty/branded medications (including GLP-1s), and operational leverage from disciplined sourcing; impacted by lower branded pharmaceutical pricing due to wholesale acquisition cost (WAC) decreases. GLP-1 distribution revenue was $1.6B in Q2; total "Triple Click" control for GLP-1s expected to remain a growth driver.
• Oncology & Multi-Specialty: Strong momentum supported by provider solutions, GPO services, and specialty distribution. Prism Vision Group expanded with Spectrum Vision Partners (150+ providers) in the Mid-Atlantic.
• Prescription Technology Solutions: Growth driven by GLP-1 medication support (including the July 1st CMS Medicare GLP-1 Bridge Program) and prior authorization services; quarterly variability expected based on utilization and payer landscape changes.
• Medical-Surgical Solutions: Growth in extended care channels offset by variability in ambulatory care due to product mix and annual illness season severity/timing.
• Biopharma Services: Added 67 new programs across 58 unique brands; payer network now covers 96% of U.S. prescription volume.

Market and Competitive Outlook:

• GLP-1 Market: Demand and volumes remain strong with significant growth ($1.6B in Q2, +26% YoY); variability expected quarter-to-quarter based on payer dynamics and patient utilization.
• 340B Program: No anticipated material financial impact; company prepared to support any channel (community, health system, or contract pharmacies) regardless of policy implementation (rebate model vs. OPPS).
• Biosimilars: Anticipate launches of a slate of biosimilars in the next 12 months; company expects to maintain margin integrity through service-based value capture.
• Customer Relationships: Extended pharmaceutical distribution agreement with CVS Health (starts October 1st, ends June 2032) reflected in outlook.
• Specialty Care Shift: Accelerating trend toward lower-cost community settings and home-based care for specialty therapies.

Macro / Industry Outlook:

• Policy Environment: Acknowledged as dynamic following the election; company plans to engage with both parties on cost, quality, access, and transparency issues.
• Clinical Trial Landscape: Increasing complexity and innovation in oncology/rare diseases driving demand for clinical research services and market access solutions.
• Regulatory: Continued monitoring of 340B implementation details; no immediate assumptions on behavioral changes by covered entities.

Strategic Initiatives:

• Precision Medicine Group (PMG) Acquisition: Closed this week for ~$2.25B (funded by cash); accretive to Fiscal 2027 EPS. Integrates into Oncology & Multi-Specialty segment to enhance clinical trial capabilities (CRO) and market access services (PrecisionAQ).
• Option Care Health Investment: Definitive agreement to invest ~$1.4B for a 49% minority interest; closing expected in the first half of calendar year 27 (subject to regulatory approval). Reported under equity method in corporate segment; not included in current EPS guidance.
• Spectrum Vision Partners: Added to PRISM Vision Group in the Mid-Atlantic region to expand provider footprint.
• Capacity & Technology: Investing in automation, AI, and robotic process automation in H2 to drive efficiency and support business growth.
• Capital Allocation: Prioritizing growth opportunities, share repurchases ($5B target for FY27), and a growing dividend.

Risks and Headwinds to Outlook:

• Seasonality & Variability: Annual illness season in Medical-Surgical Solutions may impact performance due to timing and severity; Prescription Technology Solutions subject to quarterly variability from program launches and payer changes.
• Regulatory/Pricing: Potential 340B rebate model implementation and WAC decreases impacting revenue lines (though less impact on operating profit).
• Integration: Integration of PMG expected to ramp up synergies over time; Option Care Health subject to closing conditions and governance by CD&R.
• Tax Timing: Effective tax rate phasing may vary due to timing of discrete items (higher in Q3 than Q4).

Management Tone on the Future:

• Confidence: Expressed high confidence in the business fundamentals, strategic execution, and ability to deliver long-term sustainable value.
• Outlook Revision: Raised guidance based on strong Q2 performance and first-half momentum; outlook implies EPS growth (19–21%) well above the long-term target (13–16%).
• Strategic Focus: Reaffirmed commitment to "Precision Medicine" and "Biopharma Services" as key growth platforms; viewed acquisitions as complementary and low-overlap.

Miscellaneous:

• GLP-1 Revenue: $1.6 billion in Q2, up $3 billion or 26% YoY.
• Norway Divestiture: Completed January of Fiscal 26; removed from current outlook comparisons.
• Share Repurchases: $3.4 billion purchased in the first half at an average price of $81.80 per share.